105 related articles for article (PubMed ID: 18630452)
1. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.
Mi Z; Holmes FA; Hellerstedt B; Pippen J; Collea R; Backner A; Bush JE; Gallion HH; Wells A; O'Shaughnessy JA
Anticancer Res; 2008; 28(3B):1733-40. PubMed ID: 18630452
[TBL] [Abstract][Full Text] [Related]
2. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
3. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
4. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.
Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ
Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.
Penault-Llorca F; Abrial C; Raoelfils I; Cayre A; Mouret-Reynier MA; Leheurteur M; Durando X; Achard JL; Gimbergues P; Chollet P
Hum Pathol; 2008 Aug; 39(8):1221-8. PubMed ID: 18547616
[TBL] [Abstract][Full Text] [Related]
7. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay.
Hunter EM; Sutherland LA; Cree IA; Dewar JA; Preece PE; Wood RA; Linder D; Andreotti PE
Eur J Surg Oncol; 1993 Jun; 19(3):242-9. PubMed ID: 8314382
[TBL] [Abstract][Full Text] [Related]
9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of pathological response in the breast cancer after neoadjuvant chemotherapy].
Hui R; Zhang J; Fan Y
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):961-4. PubMed ID: 18756967
[TBL] [Abstract][Full Text] [Related]
11. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW
Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
[TBL] [Abstract][Full Text] [Related]
13. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response.
Ness RB; Wisniewski SR; Eng H; Christopherson W
Anticancer Res; 2002; 22(2B):1145-9. PubMed ID: 12168915
[TBL] [Abstract][Full Text] [Related]
14. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
16. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy after neoadjuvant systemic chemotherapy in patients with breast cancer: a prospective pilot trial.
Medina-Franco H; Salgado-Nesme N; Zerón-Medina-Cuairán J
Rev Invest Clin; 2008; 60(5):390-4. PubMed ID: 19227436
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for locally advanced breast cancer.
Specht J; Gralow JR
Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
